Lung cancer (non-small cell) - erlotinib & gefitinib (post chemotherapy) (rev TA162, TA175): evaluation report

01.  Overview prepared by NICE

02.  Assessment Report prepared by LRiG

03.  Comments on the Assessment Report – AstraZeneca

04.  Comments on the Assessment Report – Roche

05.  Comments on the Assessment Report – Roy Castle Lung Cancer Foundation

06.  Comments on the Assessment Report – Royal College of Physicians

07.  Comments on the Assessment Report – Health Improvement Scotland

08.  Executive summary of technology manufacturers submission – AstraZeneca

09.  Executive summary of technology manufacturers submission – Roche

10.  Consultee submission – Royal College of Physicians

11.  Consultee submission – Roy Castle Lung Cancer Foundation

12.  Clinical expert personal perspective – Bishop

13.  Patient expert personal perspective – Fox

14.  Patient expert personal perspective – Summers

15.  Impact to ICER by changing the rate of febrile neutropenia, AG economic model results

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *

This page was last updated: 05 February 2014